Dextroamphetamine adipate
Delcobese (dextroamphetamine adipate) is a small molecule pharmaceutical. Dextroamphetamine adipate was first approved as Delcobese on 1982-01-01. It is known to target sodium-dependent dopamine transporter, sodium-dependent noradrenaline transporter, and trace amine-associated receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis | D065631 | J30.9 | — | — | 2 | — | — | 2 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | 1 | — | — | 2 |
| Sunburn | D013471 | EFO_0003958 | L55 | — | — | 2 | — | — | 2 |
| Insect bites and stings | D007299 | — | — | 2 | — | — | 2 | ||
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | — | — | 1 | |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 1 | — | — | 1 |
| Vasoplegia | D056987 | — | — | 1 | — | — | 1 | ||
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEXTROAMPHETAMINE ADIPATE |
| INN | dexamfetamine |
| Description | (S)-amphetamine is a 1-phenylpropan-2-amine that has S configuration. It has a role as a neurotoxin, an adrenergic uptake inhibitor, a dopaminergic agent, a sympathomimetic agent, a dopamine uptake inhibitor and an adrenergic agent. It is an enantiomer of a (R)-amphetamine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](N)Cc1ccccc1.O=C(O)CCCCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 51-64-9 |
| RxCUI | 3288 |
| ChEMBL ID | CHEMBL1200782 |
| ChEBI ID | — |
| PubChem CID | 5826 |
| DrugBank | DB01576 |
| UNII ID | TZ47U051FI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC6A3
SLC6A3
SLC6A2
SLC6A2
TAAR1
TAAR1
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 239 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,813 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more